| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |